Diaceutics Balance Sheet Health
Financial Health criteria checks 6/6
Diaceutics has a total shareholder equity of £38.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £45.4M and £6.7M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£16.75m |
| Equity | UK£38.74m |
| Total liabilities | UK£6.69m |
| Total assets | UK£45.43m |
Recent financial health updates
No updates
Recent updates
Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company
May 30
Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity
Jan 31Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts
Jan 28Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)
Jul 24Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?
Feb 04
Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 31Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?
Nov 27Financial Position Analysis
Short Term Liabilities: DXRX's short term assets (£27.2M) exceed its short term liabilities (£5.6M).
Long Term Liabilities: DXRX's short term assets (£27.2M) exceed its long term liabilities (£1.1M).
Debt to Equity History and Analysis
Debt Level: DXRX is debt free.
Reducing Debt: DXRX has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Debt Coverage: DXRX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: DXRX has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Diaceutics PLC is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hayley Palmer | Canaccord Genuity |
| Colin Smith | Capital Access Group |
| Oliver Juggins | Capital Access Group |